African biopharmaceutical company Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate. The investment is part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on… Read More
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV). “Vaccinating the first participants with mRNA-1469 marks an important milestone in advancing a vaccine candidate against Bundibugyo ebolavirus, for which no… Read More
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) has reported that it is working urgently with the Clinical BioManufacturing Facility and the Serum Institute of India (SIIPL) to rapidly produce and scale doses of its ChAdOx-based monovalent… Read More
A clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults. The interim results of this National Institutes of Health (NIH)-funded trial were presented at the IDWeek2024 conference in Los Angeles. Colourised transmission… Read More
An experimental vaccine against Marburg virus (MARV) was proved to be safe and induced an immune response in a small, first-in-human clinical trial. In areas of Africa where a vaccine for Marburg is most needed, a single-dose vaccine that could protect recipients over a long period of… Read More
The Rockefeller Foundation will provide $3 million in new funding for Global.health (G.h) – an open-source platform for scientific pandemic data. The investment will allow the platform to expand its international partnerships and modernise the global effort around coordinated pandemic prevention, surveillance, and response. Co-developed by researchers and engineers… Read More
